Brief: Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results From Phase 2 Radiant Study Of Remlifanserin For The Treatment Of Alzheimer’S Disease Psychosis
BRIEF-Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results From Phase 2 Radiant Study Of Remlifanserin For The Treatment Of Alzheimer’S Disease Psychosis Sept 24 (Reuters) - Acadia Pharmaceuticals Inc. ACAD.O:
ACADIA PHARMACEUTICALS ANNOUNCES PHASE 3 ENABLING TOPLINE RESULTS FROM PHASE 2 RADIANT STUDY OF REMLIFANSERIN FOR THE TREATMENT OF ALZHEIMER’S DISEASE PSYCHOSIS (ADP)
ACADIA PHARMACEUTICALS - REMLIFANSERIN DEMONSTRATED FAVORABLE SAFETY PROFILE WITH ADVERSE EVENT RATES SIMILAR TO PLACEBO
ACADIA: NARROWLY MISSED PRIMARY ENDPOINT OF SAPS H+D (P=0.0603) WITH SIGNIFICANCE (NOMINAL) ON KEY SECONDARY ENDPOINT OF CGI-S-ADP (P=0.0077)
ACADIA PHARMACEUTICALS: TO CONTINUE ENROLLING 2 ONGOING PHASE 3 STUDIES EVALUATING REMLIFANSERIN IN ADP, TO IMPLEMENT AMENDMENTS TO PHASE 3 PROGRAM
ACADIA: DATASET SUGGESTS NO NEGATIVE IMPACT ON MOTOR SYMPTOMS OR COGNITION; NO DEATHS IN REMLIFANSERIN TREATMENT ARMS
Source text: ID:nBw692H5ga
Further company coverage: ACAD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acadia Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study (updated)
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry